[1] SYURIN S,VINNIKOV D.Occupational disease predictors in the nickel pyrometallurgical production:a prospective cohort observation[J].J Occup Med Toxicol,2022,17(1):21-23. [2] TIAN B,LIU S,FENG L,et al.Renal-clearable nickel-doped carbon dots with boosted photothermal conversion efficiency for multimodal imaging-guided cancer therapy in the second near-infrared biowindow[J].Adv Funct Mater,2021,31(26):549-552. [3] YANG J,MA Z.Research progress on the effects of nickel on hormone secretion in the endocrine axis and on target organs[J].Ecotoxicol Environ Saf,2021,213(3):34-36. [4] KUO C Y,WONG R H,LIN J Y,et al.Accumulation of chromium and nickel metals in lung tumors from lung cancer patients in Taiwan[J].J Toxicol Env Heal b,Part A,2006,69(14):1337-1344. [5] GRIMSRUD T K,BERGE S R,HALDORSEN T,et al.Can lung cancer risk among nickel refinery workers be explained by occupational exposures other than nickel[J].Epidemiol,2005,12(2):146-154. [6] KHLIFI R,OLMEDO P,GIL F,et al.Arsenic,cadmium,chromium and nickel in cancerous and healthy tissues from patients with head and neck cancer[J].Sci Total Environ,2013,452(12):58-67. [7] JÄRUP L,BELLANDER T,HOGSTEDT C,et al.Mortality and cancer incidence in Swedish battery workers exposed to cadmium and nickel[J].Occup Environ Med,1998,55(11):755-759. [8] BRETT J O,SPRING L M,BARDIA A,et al.ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer[J].Breast Cancer Res,2021,23(7):1-15. [9] YADAV N,SUNDER R,DESAI S,et al.Progesterone modulates the DSCAM-AS1/miR-130a/ESR1 axis to suppress cell invasion and migration in breast cancer[J].Breast Cancer Res,2022,24(1):97-98. [10] ZHANG M,WU K,ZHANG P,et al.HOTAIR facilitates endocrine resistance in breast cancer through ESR1/miR-130b-3p axis:Comprehensive analysis of mRNA-miRNA-lncRNA network[J].Int J Gen Med,2021,8(3):4653-4663. [11] YONOVA I M,JOHNSON A G,OSBORNE C A,et al.Stereospecific nickel-catalyzed cross-coupling reactions of alkyl grignard reagents and identification of selective anti-breast-cancer agents[J].Angew Chem Int Ed,2014,53(9):2422-2427. [12] SCIANNAMEO V,RICCERI F,SOLDATI S,et al.Cancer mortality and exposure to nickel and chromium compounds in a cohort of Italian electroplaters[J].Am J Ind Med,2019,62(2):99-110. [13] AHAMED M,AKHTAR M J,ALHADLAQ H A,et al.Comparative cytotoxic response of nickel ferrite nanoparticles in human liver HepG2 and breast MFC-7 cancer cells[J].Chemosphere,2015,135(22):278-288. [14] PAVELA M,UITTI J,PUKKALA E.Cancer incidence among copper smelting and nickel refining workers in Finland[J].Am J Ind Med,2017 60(1):87-95. [15] YU M,ZHANG J.Serum and hair nickel levels and breast cancer:Systematic review and meta-analysis[J].Biol Trace Elem Res,2017 179(14):32-37. [16] TODA H,SEKI N,KUROZUMI S,et al.RNA-sequence-based microRNA expression signature in breast cancer:Tumor-suppressive miR-101-5p regulates molecular pathogenesis[J].Mol Oncol,2020,14(2):426-446. [17] NORMANN L S,HAUGEN M H,AURE M R,et al.miR-101-5p acts as a tumor suppressor in HER2-positive breast cancer cells and improves targeted therapy[J].Breast Cancer,2022,12(8):25-39. [18] YAMADA Y,NOHATA N,UCHIDA A,et al.Replisome genes regulation by antitumor miR-101-5p in clear cell renal cell carcinoma[J].Cancer Sci,2020,111(4):1392-1406. [19] HUANG C,WANG M,ZHAO W Y,et al.Long noncoding RNA SPRY4-IT1 acts as a miR-101-5p sponge to promote gastrointestinal stromal tumor progression by inhibiting ZEB1[J].Am J Transl Res,2023,15(2):1026-1028. [20] UDDEN S N,WANG Q,KUMAR S,et al.Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition[J].JCI Insight,2022,7(17):54-56. [21] MITOBE Y,IINO K,TAKAYAMA K,et al.PSF promotes ER-positive breast cancer progression via posttranscriptional regulation of ESR1 and SCFD2[J].Cancer Res,2020,80(11):2230-2242. [22] MENG J,WANG L,HOU J,et al.CCL23 suppresses liver cancer progression through the CCR1/AKT/ESR1 feedback loop[J].Cancer Sci,2021 112(8):3099-3110. [23] LI Z,SPOELSTRA N S,SIKORA M J,et al.Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer[J].NPJ Breast Cancer,2022,8(1):62. [24] TAKEIWA T,IKEDA K,SUZUKI T,et al.PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2[J].Sci Rep,2022,12(1):9495-9498. [25] LIU L,ZHANG C,QU S,et al.ESR1 inhibits ionizing radiation-induced ferroptosis in breast cancer cells via the NEDD4L/CD71 pathway[J].Arch Biochem Biophys,2022,725(24):299-302. [26] WILLIAMS M M,SPOELSTRA N S,ARNESEN S,et al.Steroid hormone receptor and infiltrating immune cell status reveals therapeutic vulnerabilities of ESR1-mutant breast cancer[J].Cancer Res,2021,81(3):732-746. [27] HUANG C,WANG M,ZHAO W Y,et al.Long noncoding RNA SPRY4-IT1 acts as a miR-101-5p sponge to promote gastrointestinal stromal tumor progression by inhibiting ZEB1[J].Am J Transl Res,2023,15(2):1026-1028. |